No Data
No Data
Kelon Botai Biotechnology-B (06990.HK) plans to hold a board of directors meeting on August 19th to approve its mid-term performance.
Kolon Life Science-B (06990.HK) announced on August 7th that the board of directors will hold a board meeting on August 19, 2024 (Monday) to consider and approve the mid-term performance of the company and its subsidiaries for the six-month period ended June 30, 2024, as well as to handle other matters.
SKB BIO-B: NOTICE OF BOARD MEETING
Hong Kong stock concept tracking | National Medical Products Administration approved the pilot program of optimizing the clinical trial review and approval of innovative drugs in Peking and Shanghai, and innovative drugs are expected to outperform other s
The pharmaceutical industry is expected to see overall year-on-year improvement and quarter-on-quarter growth in performance in the second half of the year.
China Post Securities: ADC drug innovation drives development, and the industry's high prosperity continues.
Several varieties with sales amounts reaching tens of billions of yuan are expected to emerge in the domestic ADC drug field, with many biopharmaceutical and biotechnology companies focused on layout. It is recommended to actively pay attention to pharmaceutical companies with smooth clinical progress and overseas prospects.
Minsheng Securities: First-time recommendation to Kolon Biotec-B (06990) with a target price of HKD 187.1.
Minsheng Securities expects that the net income attributable to the parent company of Kebotai Biotechnology-B (06990) in 2024-2026 will be -0.888 billion yuan, -0.781 billion yuan, and -0.305 billion yuan, respectively.
China Securities Co., Ltd. expects that the "expanding domestic demand" trade will gradually grow, covering cyclical and growth stocks.
China Securities Co.,Ltd. released a research report stating that it is expected that the 'expanding domestic demand' trade will gradually grow, covering both cyclical and growth stocks.
No Data